Protalix BioTherapeutics, Inc. (DE) (PLX)
PLX moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How PLX actually reacts to news — the realized, point-in-time move the market made, measured across 197 labeled events over the last three years with zero look-ahead.
PLX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 36% | 197 |
| 30-min | 0.00% | 43% | 197 |
| 60-min | 0.00% | 49% | 197 |
| to close | 0.00% | 50% | 194 |
| Middle 50% of PLX reactions | -1.25% to +1.15% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 197 |
Half of all Protalix BioTherapeutics, Inc. (DE) news events land between -1.25% and +1.15% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when PLX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PLX's baseline. Nothing else.
Recent PLX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences | Press release | PR Newswire | -1.13% | -0.38% | |
| Form 10-Q Protalix BioTherapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.21% | +5.22% | |
| Form 8-K Protalix BioTherapeutics For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -1.21% | +5.22% | |
| Form S-8 Protalix BioTherapeutics | SEC filing · Form S-8 | SEC EDGAR | -1.21% | +5.22% | |
| Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results | Press release | PR Newswire | -1.21% | +5.22% | |
| Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026 | Press release | PR Newswire | +0.00% | +2.09% | |
| Form 8-K Protalix BioTherapeutics For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | -0.23% | +3.60% | |
| Form 8-K Protalix BioTherapeutics For: May 21 | SEC filing · Form 8-K | SEC EDGAR | +0.51% | +2.52% | |
| Form 10-Q Protalix BioTherapeutics For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +7.11% | -2.03% | |
| Form 8-K Protalix BioTherapeutics For: May 13 | SEC filing · Form 8-K | SEC EDGAR | +7.11% | -2.03% | |
| Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results | Press release | PR Newswire | +7.11% | -2.03% | |
| Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026 | Press release | PR Newswire | -2.00% | +1.00% | |
| Form ARS Protalix BioTherapeutics For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | -1.85% | |
| Form DEF 14A Protalix BioTherapeutics For: Jun 25 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -1.85% | |
| Form 10-K Protalix BioTherapeutics For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -7.49% | -3.07% | |
| Form 8-K Protalix BioTherapeutics For: Mar 18 | SEC filing · Form 8-K | SEC EDGAR | -7.49% | -3.07% | |
| Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results | Press release | PR Newswire | -7.49% | -3.07% | |
| Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026 | Press release | PR Newswire | +1.04% | +0.70% | |
| Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) | Press release | GlobeNewswire | +3.77% | +8.68% | |
| Form 8-K Protalix BioTherapeutics For: Mar 09 | SEC filing · Form 8-K | SEC EDGAR | +3.77% | +8.68% | |
| Form 8-K Protalix BioTherapeutics For: Feb 11 | SEC filing · Form 8-K | SEC EDGAR | +0.34% | -2.39% | |
| Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU | Press release | GlobeNewswire | +3.42% | +10.51% | |
| Form 8-K Protalix BioTherapeutics For: Jan 30 | SEC filing · Form 8-K | SEC EDGAR | +0.02% | +3.79% | |
| Form 8-K Protalix BioTherapeutics For: Jan 05 | SEC filing · Form 8-K | SEC EDGAR | +2.30% | +2.87% | |
| Protalix BioTherapeutics Letter to Stockholders | Press release | PR Newswire | +2.30% | +2.87% | |
| Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement | Press release | PR Newswire | +0.00% | -4.35% | |
| Form 10-Q Protalix BioTherapeutics For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +6.52% | — | |
| Form 8-K Protalix BioTherapeutics For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | +6.52% | — | |
| Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results | Press release | PR Newswire | +6.52% | — | |
| Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025 | Press release | PR Newswire | -1.91% | -5.93% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Protalix BioTherapeutics, Inc. (PLX) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.21% | +1.06% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Protalix BioTherapeutics, Inc. (PLX) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +0.00% | -1.06% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Protalix BioTherapeutics, Inc. (PLX) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.00% | +2.80% | |
| Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU | Press release | GlobeNewswire | -0.87% | +1.30% | |
| Form 8-K Protalix BioTherapeutics For: Nov 03 | SEC filing · Form 8-K | SEC EDGAR | -0.87% | +1.30% | |
| Protalix BioTherapeutics, Inc. (PLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.65% | +2.15% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Protalix BioTherapeutics, Inc. (PLX) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +2.22% | +5.10% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Protalix BioTherapeutics, Inc. (PLX) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.42% | +0.85% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Protalix BioTherapeutics, Inc. (PLX) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -2.47% | -2.06% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Protalix BioTherapeutics, Inc. (PLX) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.00% | +3.82% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Protalix BioTherapeutics, Inc. (PLX) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.46% | +3.18% | |
| Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU | Press release | GlobeNewswire | -2.68% | +10.71% | |
| Form 8-K Protalix BioTherapeutics For: Oct 17 | SEC filing · Form 8-K | SEC EDGAR | -2.68% | +10.71% | |
| Protalix BioTherapeutics to Present at Investor Summit Virtual | Press release | ACCESS Newswire | +0.00% | +0.58% | |
| Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference | Press release | PR Newswire | +2.80% | +4.46% | |
| Form EFFECT Protalix BioTherapeutics | SEC filing · Form EFFECT | SEC EDGAR | +0.30% | -2.44% | |
| Form 8-K Protalix BioTherapeutics For: Aug 22 | SEC filing · Form 8-K | SEC EDGAR | +0.30% | -2.44% | |
| Form 10-Q Protalix BioTherapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -2.56% | |
| Form 8-K Protalix BioTherapeutics For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.56% | |
| Form S-3/A Protalix BioTherapeutics | SEC filing · Form S-3 | SEC EDGAR | +0.00% | -2.56% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PLX section they belong to.
Where else PLX is measured.
PLX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | 198 | -0.18% | 44% |
| Inogen, Inc (INGN) | 197 | +0.31% | 60% |
| AC Immune SA (ACIU) | 195 | -0.43% | 42% |
| Stereotaxis, Inc. (STXS) | 195 | +0.23% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Protalix BioTherapeutics, Inc. (DE)'s median reaction calculated?
Every labeled PLX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 197 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of PLX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PLX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.